% Expired Patents = 50.0

Forward Citations = 1

Loading Chart...

5 inventors (with patents filed for the assignee):

David Lawrence Selwood (4 out of 17 patents)

Masahiro Okuyama (1 out of 11 patents)

David Baker (1 out of 7 patents)

4. Cristina Visintin (1 out of 3 patents)

5. Gareth Pryce (1 out of 3 patents)

4 patents: Sort by Forward Citations

1. 9908843 - Benzamide derivatives useful in the treatment of muscular disorders and pain and for controlling spasticity and tremors (2018-03-06),

2. 9682924 - Crystalline form of VSN16 (2017-06-20),

3. 9120723 - Modulator (2015-09-01),

4. 9024067 - Process for preparing carboxylic acid amides useful in the treatment of muscular disorders (2015-05-05),

Company Overview

Canbex Therapeutics Limited is a biopharmaceutical company focused on developing new drugs to treat neurological disorders. Their lead product candidate is currently in Phase II clinical trials for the treatment of spasticity, a common symptom of multiple sclerosis.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

4 Patents

#657 in London

#3,863 in United Kingdom

London, United Kingdom

Canbex Therapeutics Limited

Forward Citations = 1

5 inventors:

David Lawrence Selwood (4 out of 17 patents)

Masahiro Okuyama (1 out of 11 patents)

David Baker (1 out of 7 patents)

4. Cristina Visintin (1 out of 3 patents)

5. Gareth Pryce (1 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Canbex Therapeutics Limited. Retrieved from https://idiyas.com/company/canbex-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]